232 results on '"Hong, Chih-ho"'
Search Results
2. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials
3. Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
4. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
5. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
6. Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysis
7. Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
8. Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
9. Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
10. Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks
11. Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis
12. Practical Management of Patients with Atopic Dermatitis on Dupilumab
13. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
14. Psoriasis Prevalence and Severity by Expert Elicitation
15. 549 - Laboratory parameters in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial
16. Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial
17. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials
18. Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial
19. The Treat-to-Target Project in Atopic Dermatitis: One Year On
20. Management and Treatment of Atopic Dermatitis in Primary Care
21. Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application
22. Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial
23. Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial
24. The Treat-to-Target Project in Atopic Dermatitis:One Year On
25. 308 Tralokinumab provides other clinically meaningful improvements in adolescents with moderate-to-severe atopic dermatitis who did not achieve IGA 0/1 at week 16
26. Follow-up of Patients With Keratinocyte Carcinoma
27. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway
28. The impact of tralokinumab on quality of life and school in patients aged 12–17 with atopic dermatitis: results from the phase 3 ECZTRA 6 trial
29. Exposure–Response Analysis Demonstrates Response to Tapinarof is Driven by Local Effects at Sites of Application
30. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial
31. 50376 Prevalence and Clinical Correlates of Apathy in Psoriatic Disease
32. 53025 Roflumilast cream 0.3% in patients with psoriasis: Improvement in patient reported outcomes and pruritus from two pooled phase 3 trials (DERMIS-1/DERMIS-2)
33. Dupilumab: A review of its use in the treatment of atopic dermatitis
34. Management of moderate‐to‐severe plaque psoriasis with biologics: A treat‐to‐target position paper
35. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis
36. Practice Patterns Around the Management of Atopic Dermatitis in 2018 and 2020
37. Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study
38. Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial
39. Supplementary material - Supplemental material for Practice Patterns Around the Management of Atopic Dermatitis in 2018 and 2020
40. Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
41. Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study
42. Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies
43. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study
44. 28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
45. 27519 Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
46. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors
47. Efficacy, pharmacokinetics, and tolerability of subcutaneous secukinumab injections with 2 mL prefilled syringes (300 mg) in adult subjects with moderate to severe plaque psoriasis
48. Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies
49. 43997 Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND
50. 44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.